Morie Gertz, MD, MACP, Mayo Clinic, Rochester, MN, discusses the goal of therapy in immunoglobulin light chain (AL) amyloidosis and what predicts the best outcome, highlighting that free light chain ratio should not be used as a criterion or endpoint of therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
